Andrew James King - 29 Jul 2023 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC.

Role: Chief Scientific Officer
Signature: /s/ Kirk Schumacher, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 29 Jul 2023
Net transactions value: -$45,586
Form type: 4
Filing time: 01 Aug 2023, 19:27:27 UTC
Previous filing: 05 Apr 2023
Next filing: 11 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KDNY	Common Stock	Options Exercise		+3,333	+20%		20,325	29 Jul 2023	Direct	F1
transaction	KDNY	Common Stock	Sale	$45,586	-1,168	-5.7%	$39.03	19,157	01 Aug 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KDNY	Restricted Stock Units	Options Exercise	$0	-3,333	-33%	$0.000000	6,667	29 Jul 2023	Common Stock	3,333		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3	Each RSU represents a contingent right to receive one share of Issuer's common stock.
F4	The RSUs vest as to one-third (1/3) of the total award on the first, second, and third anniversaries of the grant date, subject to the reporting person's continued service to the Issuer on each vesting date.